Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 5/20 | 0.65 |
| ▸ | TBXAS1 | P24557 | 12/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514462 | 1.00 | GPR52 (0.65) | GPR52TBXAS1NAPRTCHRNA7 | |
| SCHEMBL11062795 | 0.90 | TBXAS1 (0.67) | GPR52TBXAS1 | |
| SCHEMBL11062791 | 0.90 | TBXAS1 (0.67) | GPR52TBXAS1 | |
| SCHEMBL8512647 | 0.89 | GPR52 (0.57) | GPR52TBXAS1NAPRTCHRNA7 | |
| SCHEMBL8512649 | 0.89 | GPR52 (0.57) | GPR52TBXAS1NAPRTCHRNA7 | |
| SCHEMBL15758205 | 0.83 | TBXAS1 (0.57) | GPR52TBXAS1NAPRT | |
| SCHEMBL15758203 | 0.83 | TBXAS1 (0.57) | GPR52TBXAS1NAPRT | |
| SCHEMBL11065494 | 0.82 | TBXAS1 (0.64) | GPR52TBXAS1 | |
| SCHEMBL11065492 | 0.82 | TBXAS1 (0.64) | GPR52TBXAS1 | |
| SCHEMBL2853636 | 0.81 | GPR52 (0.70) | GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10144731-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083614-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092713-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| WO-2012069605-A1 | NOVEL E,E-DIENE COMPOUNDS AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | GPR52 569/4885TBXAS1 1055/4885NAPRT 1663/4885 |
| US-20160318917-A1 | NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | GPR52 569/4885TBXAS1 1055/4885NAPRT 1663/4885 |
| US-10144731-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | GPR52 569/4885TBXAS1 1055/4885NAPRT 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.